文献速递质量管理与危急值临床生化临床免疫

统计评估是否足够?通过临床性能构建新的外部质量评估性能指标

Is statistical evaluation sufficient? New external quality assessment performance metrics through clinical performance.
PubMed 文献 · Clin Chem Lab Med · 2026-06-19

该研究基于单一临床实验室45个分析物连续12轮月度EQA数据,提出整合生物学变异的SDIRCV和pSDI两个新指标,并通过五区一致性框架和方差分量分析评估。结论认为新指标可检测传统EQA标准的假接受和假拒绝。

要点

  • SDIRCV和pSDI整合生物学变异,可识别SDI可接受但临床显著偏差。
  • 540次观察中1.67%为生物学显著但统计未检出偏差。
  • 24%分析物SDIRCV中位数<2.0,存在持续脆弱区。

核心结论

  • SDIRCV和pSDI能检测传统EQA标准固有的假接受和假拒绝,提供基于生物学变异的实验室质量评估框架。

研究设计与样本

  • 分析单一临床实验室45个分析物(26个生化、19个免疫)连续12轮月度EQA结果,共540次观察。
  • 采用方差分量分析将总不精密度分解为月内重复性、月间变异和试剂批间变异。

主要发现

  • 540次观察中9次(1.67%)满足生物学显著但统计未检出偏差标准(-2<SDI<+2但pSDI≥+100%或≤-100%)。
  • 4次观察(0.74%)显示临床无意义SDI超标(SDI≥+3或≤-3但-100%<pSDI<+100%)。
  • 试剂批间变异中位数占总方差23.6%,6个分析物超过50%。

关键数值与推荐

  • SDIRCV定义为参考变化值(RCV)与同行组变异系数的比值。
  • pSDI将EQA偏差表示为RCV的百分比。
  • 传统SDI接受标准为-2<SDI<+2。
  • 五区一致性框架通过交叉制表传统SDI和pSDI标准构建。

临床怎么用

  • 检验科可引入SDIRCV和pSDI补充传统SDI,识别临床显著但统计未检出的偏差。
  • 对SDIRCV中位数<2.0的分析物应关注持续脆弱性。
  • 试剂批间变异占比高的分析物需加强批间比对和质量管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: External Quality Assessment (EQA) programmes conventionally use the Standard Deviation Index (SDI) with an analyte-independent acceptance criterion of -2<SDI<+2, which does not account for biological variation or clinical relevance. We developed two novel metrics, the biologically calibrated tolerance index (SDIRCV) and percentage SDI (pSDI), that integrate biological variation into EQA interpretation and quantified the sources of analytical imprecision through variance component analysis (VCA). METHODS: Monthly EQA results from 12 consecutive survey cycles were analysed for 45 analytes (26 biochemistry, 19 immunoassay) in a single clinical laboratory. SDIRCV was defined as the ratio of the reference change value (RCV) to the peer-group coefficient of variation. The pSDI expressed EQA bias as a percentage of the RCV. A five-zone concordance framework was constructed by cross-tabulating conventional SDI and pSDI criteria. A three-level VCA decomposed total imprecision into within-month repeatability, between-month variation, and reagent lot-to-lot variation. RESULTS: Of 540 observations, nine (1.67 %) met the Biologically Significant, Statistically Undetected Deviation criterion (-2<SDI<+2 yet pSDI≥+100 % or ≤-100 %), indicating clinically significant bias despite acceptable SDI. Four observations (0.74 %) showed Clinically Inconsequential SDI Exceedance (SDI≥+3 or ≤-3 yet -100 %<pSDI<+100 %). Eleven analytes (24 %) had median SDIRCV<2.0, defining a persistent vulnerability zone. Lot-to-lot variation accounted for a median of 23.6 % of the total variance, exceeding 50 % for six analytes. CONCLUSIONS: SDIRCV and pSDI detect both false acceptance and false rejection inherent in conventional EQA criteria, offering a biologically grounded framework for aligning laboratory quality assessment with clinical needs.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Akbay Hİ, Theodorsson E, Alp HH, et al. Is statistical evaluation sufficient? New external quality assessment performance metrics through clinical performance. Clin Chem Lab Med. 2026. PMID: 42310997. doi:10.1515/cclm-2026-0702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。